Dexmedetomidine hydrochloride is a Small Molecule owned by Orion, and is involved in 82 clinical trials, of which 68 were completed, 13 are ongoing, and 1 is planned.

Dexmedetomidine Hydrochloride is the hydrochloride salt form of dexmedetomidine, an imidazole derivate and active d-isomer of medetomidine with analgesic, anxiolytic and sedative activities. Dexmedetomidine selectively binds to and activates presynaptic alpha-2 adrenoceptors located in the brain, thereby inhibiting the release of norepinephrine from synaptic vesicles. This leads to an inhibition of postsynaptic activation of adrenoceptors, which inhibits sympathetic activity, thereby leading to analgesia, sedation and anxiolysis.

The revenue for Dexmedetomidine hydrochloride is expected to reach a total of $6.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dexmedetomidine hydrochloride NPV Report.

Dexmedetomidine hydrochloride is originated and owned by Orion. Pfizer is the other company associated in development or marketing of Dexmedetomidine hydrochloride.

Dexmedetomidine hydrochloride Overview

Dexmedetomidine Hydrochloride (Precedex, Dexdor, Xamdex) is a sedative agent. It is formulated as concentrate solution, injectable solution and powder for solution for intravenous route of administration. Dexmedetomidine Hydrochloride is used for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. It is also indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures. Dexmedetomidine (DEX-IN, DEX-TD, DEX-SL) is under development as a non-intravenous formulation for the treatment of cancer pain, peri procedural pain and acute pain in adult patients undergoing hallux valgus (Bunion) surgery. It was also under development for the treatment of post operative pain and chronic lower back pain.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – Dexmedetomidine hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Dexmedetomidine hydrochloride
Administration Pathway
  • Intravenous
  • Nasal
  • Sublingual
  • Transdermal
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.